The Evolution in Non-Alcoholic Fatty Liver Disease Patients' Profile and the Associated Sustainable Challenges: A Multidisciplinary Perspective
- PMID: 38892517
- PMCID: PMC11174485
- DOI: 10.3390/nu16111584
The Evolution in Non-Alcoholic Fatty Liver Disease Patients' Profile and the Associated Sustainable Challenges: A Multidisciplinary Perspective
Abstract
The prevalence and incidence of NAFLD is rising due to the obesity pandemic, caused by the widespread availability of ultra-processed foods and the decrease of physical activity. Factors such as socioeconomic status (SES), ethnicity and geographical location are associated with NAFLD, with lower SES correlating with higher incidence, particularly in regions like America or Europe. Beside the quality of food, the quantity also plays a crucial role. The World Health Organization (WHO) recommends a Mediterranean diet with a balanced energy intake. Since no hard medical treatment is available for NAFLD, lifestyle adjustments are key. Patient empowerment by providing relevant information and co-ownership of the therapy will increase the implementation rate and enhance the quality of medical follow-up and medication adherence, as studies report a good adherence to medication among patients who are well-aware of the severity of their disease. Regarding sustainability, patients with NAFLD have a high load of ambulatory follow-up, which, since the COVID-19 pandemic, can be partially provided by teleconsulting. Both patients' lifestyle modifications and healthcare practitioners' therapeutical strategy can decrease the carbon footprint.
Keywords: NAFLD; cirrhosis; nutrition; sustainability; waste.
Conflict of interest statement
E.D.W. reported receiving honoraria for advisory board meetings, lectures, and travel expenses from Baxter Healthcare, Danone-Nutricia, Cardinal Health, Fresenius Kabi, GE Healthcare, ART Medical, and Ferring Pharmaceuticals. The other authors had no conflict of interest in this study.
Figures


References
-
- Estes C., Anstee Q.M., Arias-Loste M.T., Bantel H., Bellentani S., Caballeria J., Colombo M., Craxi A., Crespo J., Day C.P., et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J. Hepatol. 2018;69:896–904. doi: 10.1016/j.jhep.2018.05.036. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical